Any experience with Epitalon + Vilon (or just Vilon)

Researcher6076

Researcher6076

GLP-1 Apprentice
Member Since
Feb 3, 2026
Posts
118
Likes Received
327
Location
Hawaii
I have had good results with a partial test of Thymalin + Epitalon and plan to run the full protocol of 10mg Thymalin + 10mg Epitalon daily for 10 days, for a total of 100mg each. My partner tends toward autoimmune issues, not serious, but her goal is to normalize her immune system as much as possible. I've seen referneces to a Khavinson protocol for 10mg Epitalon + 5mg Vilon daily for 10 day. The biological mechanisms make sense.

Can anyone share any experiences with Vilon?
 
Researcher6076 said:
I have had good results with a partial test of Thymalin + Epitalon and plan to run the full protocol of 10mg Thymalin + 10mg Epitalon daily for 10 days, for a total of 100mg each. My partner tends toward autoimmune issues, not serious, but her goal is to normalize her immune system as much as possible. I've seen referneces to a Khavinson protocol for 10mg Epitalon + 5mg Vilon daily for 10 day. The biological mechanisms make sense.

Can anyone share any experiences with Vilon?
Click to expand...
Take a look at that Epithalon dose. Somewhere along the way the dosing got a bit distorted.
The original Russian research most people reference was actually done with epithalamin, which was a pineal gland extract containing multiple peptides. Epithalon is the isolated synthetic tetrapeptide from that extract, so it’s not exactly the same compound.
The 10 mg/day protocol came from those epithalamin studies, and a lot of people just carried that dose over to Epithalon. For the pure peptide, that can end up being a really large dose.
If you search the forum here you’ll find quite a few threads discussing this and people adjusting downward.
I’m also speaking from experience. I made the same mistake and started at that dose. I felt pretty awful for a day or two before digging in and realizing the dosing confusion. Once I dialed it in properly the experience was completely different and honestly pretty amazing for me.
 
Did you guys get whacked dreams at 10mg injections?

I'm planning on dosing late march after I run this SS31, before MOTS-c, but imma just dose 1mg, as suggested by several others.
 
trojanpeptide said:
Did you guys get whacked dreams at 10mg injections?

I'm planning on dosing late march after I run this SS31, before MOTS-c, but imma just dose 1mg, as suggested by several others.
Click to expand...
O YES...... I have a post about that on this forum.. if you find it you will laugh..
 
CNCCurrency said:
I understood there maybe cancer risks with vilon? Research from the International Journal of Cancer showed that in HER-2/neu transgenic mice (a breast cancer model), Vilon increased the incidence of mammary cancer and shortened tumor development time
Click to expand...
Thanks so much for bringing up cancer risks. I failed to focus on those. I looked at the article and it referred to Epitalon, not Vilon. But I mentioned I want to run both peptides together.

First, the Vilon research I can find shows

Epigenetic reactivation, not random proliferation
Vilon decondenses facultative heterochromatin and reactivates silenced genes in aging lymphocytes, without disrupting structural pericentromeric heterochromatin. That’s a targeted epigenetic effect, not a blunt mitogenic push.

Immune normalization and anti‑inflammatory effects
In experimental models, Vilon tends to normalize lymphocyte responses and modulate immune activation rather than drive unchecked proliferation.

Tumor inhibition and lifespan extension in animals
Russian‑lineage summaries and secondary reviews describe Vilon as associated with tumor inhibition and lifespan extension in animal models, though details are sparse and not always in primary English‑language papers.

Cancer‑prevention framing, not oncogenic
Modern overviews explicitly discuss Vilon in the context of cancer prevention—via immune surveillance, modulation of signaling, and anti‑inflammatory/antioxidant effects—rather than as a potential carcinogen.

But there is still come reason for caution

Epigenetic reactivation is powerful biology
Any agent that can “turn genes back on” in aging cells—like Vilon’s deheterochromatinization of facultative heterochromatin—theoretically could unmask dormant oncogenic programs as well as beneficial ones. That’s a conceptual, not observed, risk.

No long‑term human cancer‑incidence data
We don’t have large, long‑duration human cohorts on Vilon with cancer outcomes tracked the way we do (partially) for Thymalin/Epithalamin. So the safety picture is incomplete, not clearly negative.

Epitalon was the peptide discussed in that article. Here’s what I know about Epitalon and cancer, also factoring in that article

Mechanism that worries people:
Epitalon can activate telomerase and lengthen telomeres in normal human cells. Since most cancers rely on telomerase to stay immortal, anything that boosts telomerase is theoretically pro‑tumor.

What preclinical data actually show:
In multiple animal cancer models, Epitalon has tended to delay tumor appearance, reduce tumor number/size, or inhibit metastasis, rather than accelerate cancer.

Differential effect in normal vs cancer cells:
That 2025 paper found Epitalon:

Upregulated telomerase and lengthened telomeres in normal cells

But in breast cancer cell lines, it mainly activated ALT (Alternative Lengthening of Telomeres) rather than simply cranking telomerase. That suggests its telomere biology in cancer cells is not at all straightforward.

Human data:

No large, modern randomized trials tracking cancer incidence on Epitalon.

Older Russian‑lineage work and later reviews highlight possible cancer‑preventive effects, but replication outside those groups is limited.

Background telomere science:
Mendelian randomization studies show that people born with genetically longer telomeres have higher risks of several cancers, which is why any telomere‑lengthening agent is treated with caution conceptually.

In conclusion, published Vilon data leans anti‑tumor, not pro‑cancer, but its epigenetic “gene‑reactivating” action means we can’t say zero risk. There are no human data showing Vilon causes cancer.

Published Epitalon data shows no clinical evidence that Epitalon increases cancer risk in humans, preclinical work is actually more anti‑tumor than pro‑tumor, but, mechanistically, its telomerase/epigenetic effects mean theoretical risk can’t be ruled out, especially in someone with active or high‑risk malignancy.

The real gap is long‑term, independent human data. As always, when there are few, or no, long-term human trails we depend on animal data or mechanistic assumptions. When it comes to really scary outcomes like cancer we should always think carefully.
 
CNCCurrency said:
even still that could have 100's of times higher than needed
Click to expand...
Several clinics and wellness/anti-aging sites still list or reference 5–10 mg/day (often for 10–20 days per cycle) as part of their Epithalon (or Epitalon) protocols. This dosing typically draws from older/traditional Russian/Khavinson-inspired approaches (originally for Epithalamin extract but carried over to synthetic Epithalon in many cases). Here are some specific examples from current or recent sources:
  • Happy Hormones MD (happyhormonesmd.com): Recommends 10 mg (e.g., 0.5 ml of 20 mg/ml solution) subcutaneously every other day for 10 days (or adjusted equivalents), cycled twice a year. They provide reconstitution guides for 10 mg and 50 mg vials to support 10-day cycles at that level.
  • Peptide Dosages / Peptidedosages.com: Lists 5 mg (5,000 mcg) once daily for 20 days as a typical protocol, with alternatives like 10 mg/day for 10 days (total cycle dose ~100 mg). They note this as based on published research protocols.
  • AgeMed / A4M-related presentation (agemed.org PDF on "The Fountain of Youth Peptide Epitalon"): Explicitly recommends 5 mg SQ daily for 10 days (total 50 mg cycle), repeated every 6 months. References Khavinson studies with Epithalamin at similar totals (e.g., 50 mg per course via 10 mg every 3 days).
  • Hubmed Ed (hubmeded.com): States standard dosage 5-10 mg per day for 10-20 days, often divided into two doses, repeated 1-2 cycles per year for longevity benefits.
  • Wellness at Century City (wellnessatcenturycity.com): Common regimen of 10 mg per day for 10-20 days, followed by a break, administered via subQ or IM.
  • Dr. Rob Berberian (drrobberberian.com, Newport Beach clinic): Typical dosages 5-10 mg per day, divided into two daily doses (morning/evening), for 10-20 day cycles.
  • Peptide Initiative / The Peptide Report: Starting dose 5 mg once daily for 10 days (classic Russian protocol), with alternatives up to 10 mg daily.
  • Other mentions (e.g., Swolverine, NewTropin, Pulse and Remedy, Holistic Medical Wellness): Frequently cite 5-10 mg/day for 10-20 days as standard research or clinic protocols, often referencing Khavinson or similar.
These higher ranges (5–10 mg/day) are still actively promoted on some U.S.-based wellness clinics
 
CNCCurrency said:
Check out the link below, even 1 mg could be 90% to high

https://pep-pedia.org/peptides/epitalon
Click to expand...
I noticed for lifespan extension, Pep-pedia mentions doses in animal studies were 30 to 40 ug PER kg. For me, at 150 lbs/68 kg, that's 2.72 mg.

My spouse, my mom, and I have all been cycling 10 mg/day x 20 days, twice/year. More than what's recommended above, but without any adverse effects.

I see that cancer growth is a theoretical adverse effect, but in practice, Epitalon appears to be anti-cancer. Are there any known adverse effects?
 
cheaperseeker said:
I noticed for lifespan extension, Pep-pedia mentions doses in animal studies were 30 to 40 ug PER kg. For me, at 150 lbs/68 kg, that's 2.72 mg.

My spouse, my mom, and I have all been cycling 10 mg/day x 20 days, twice/year. More than what's recommended above, but without any adverse effects.

I see that cancer growth is a theoretical adverse effect, but in practice, Epitalon appears to be anti-cancer. Are there any known adverse effects?
Click to expand...
I was referring to only vilon when I posted about the cancer risk above! Not sure why everyone is taking it that I was speaking to epitalon.

Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon® (Ala-Glu-Asp-Gly) or with the peptide Vilon® (Lys-Glu) in a single dose of 1 μg/mouse for 5 consecutive days every month. Epitalon treatment reduced the cumulative number and the maximum size of tumors (p < 0.05). Furthermore, the number of mice bearing 1 mammary tumor was increased, whereas the number of mice bearing 2 or more mammary tumors was reduced in Epitalon-treated in comparison to saline-treated animals (p < 0.05). The size but not the number of lung metastases was reduced in Epitalon-treated compared to saline-treated mice (p < 0.05). The treatment with Vilon produced significant negative effects when compared to the control group, with an increased incidence of mammary cancer development (p < 0.05), a shorter mean latent period of tumors (p < 0.05) and an increased cumulative number of tumors (p < 0.05). A 3.7-fold reduction in the expression of HER-2/neu mRNA was found in mammary tumors from HER-2/neu transgenic mice treated with Epitalon compared to control animals. The expression of mRNA for HER-2/neu was also partially reduced in Vilon-treated mice, but it remained significantly higher in Vilon- than in Epitalon-treated animals (1.9-fold increase). The data demonstrate the inhibitory effect of Epitalon in the development of spontaneous mammary tumors in HER-2/neu mice, suggesting that a downregulation of HER-2/neu gene expression in mammary adenocarcinoma may be responsible, at least in part, for the antitumor effect of the peptide. © 2002 Wiley-Liss, Inc.
 
CNCCurrency said:
I was referring to only vilon when I posted about the cancer risk above! Not sure why everyone is taking it that I was speaking to epitalon.

Female FVB/N HER-2/neu transgenic mice from the age of 2 months were subcutaneously injected with saline, the peptide Epitalon® (Ala-Glu-Asp-Gly) or with the peptide Vilon® (Lys-Glu) in a single dose of 1 μg/mouse for 5 consecutive days every month. Epitalon treatment reduced the cumulative number and the maximum size of tumors (p < 0.05). Furthermore, the number of mice bearing 1 mammary tumor was increased, whereas the number of mice bearing 2 or more mammary tumors was reduced in Epitalon-treated in comparison to saline-treated animals (p < 0.05). The size but not the number of lung metastases was reduced in Epitalon-treated compared to saline-treated mice (p < 0.05). The treatment with Vilon produced significant negative effects when compared to the control group, with an increased incidence of mammary cancer development (p < 0.05), a shorter mean latent period of tumors (p < 0.05) and an increased cumulative number of tumors (p < 0.05). A 3.7-fold reduction in the expression of HER-2/neu mRNA was found in mammary tumors from HER-2/neu transgenic mice treated with Epitalon compared to control animals. The expression of mRNA for HER-2/neu was also partially reduced in Vilon-treated mice, but it remained significantly higher in Vilon- than in Epitalon-treated animals (1.9-fold increase). The data demonstrate the inhibitory effect of Epitalon in the development of spontaneous mammary tumors in HER-2/neu mice, suggesting that a downregulation of HER-2/neu gene expression in mammary adenocarcinoma may be responsible, at least in part, for the antitumor effect of the peptide. © 2002 Wiley-Liss, Inc.
Click to expand...
I replied to your post, but also referenced info about Epitalon and cancer from Researcher6076's post. Sorry for the confusion.
 
Jfrick11 said:
Take a look at that Epithalon dose. Somewhere along the way the dosing got a bit distorted.
The original Russian research most people reference was actually done with epithalamin, which was a pineal gland extract containing multiple peptides. Epithalon is the isolated synthetic tetrapeptide from that extract, so it’s not exactly the same compound.
The 10 mg/day protocol came from those epithalamin studies, and a lot of people just carried that dose over to Epithalon. For the pure peptide, that can end up being a really large dose.
If you search the forum here you’ll find quite a few threads discussing this and people adjusting downward.
I’m also speaking from experience. I made the same mistake and started at that dose. I felt pretty awful for a day or two before digging in and realizing the dosing confusion. Once I dialed it in properly the experience was completely different and honestly pretty amazing for me.
Click to expand...
It's hard to find a strait, researched answer with dosing for Epitalon. Yes, the early Russian clinical trials started with epitalamin at 10mg/day. But the later Russian trials switched to Epitalon and kept the dose to 10mg day. And because epitalamin is a natural extract there is no reliable dose comparison to Epitalon. Some say 1000:1, but some say 3:1. I have found there is not reliable ratio. Yes, in our community there are lot of dosing claims, but I haven't found any actually tied to repeatable research. And 10mg of Epitalon gets used a lot with no adverse reactions reportee, right? I'm not saying you should use 10mg. Just saying there is legitimate confusion, and no clear answer.
 
Researcher6076 said:
It's hard to find a strait, researched answer with dosing for Epitalon. Yes, the early Russian clinical trials started with epitalamin at 10mg/day. But the later Russian trials switched to Epitalon and kept the dose to 10mg day. And because epitalamin is a natural extract there is no reliable dose comparison to Epitalon. Some say 1000:1, but some say 3:1. I have found there is not reliable ratio. Yes, in our community there are lot of dosing claims, but I haven't found any actually tied to repeatable research. And 10mg of Epitalon gets used a lot with no adverse reactions reportee, right? I'm not saying you should use 10mg. Just saying there is legitimate confusion, and no clear answer.
Click to expand...
That's pretty much why I've stuck to the higher dosage. I haven't seen any reliable, research-based evidence that the lower doses are effective, many sources still recommend the higher doses, and there don't seem to be any known adverse effects. If I'm going to the trouble of buying and pinning, I want to be sure, or at least as sure as I can be, that I'm getting the full benefits.
 
cheaperseeker said:
That's pretty much why I've stuck to the higher dosage. I haven't seen any reliable, research-based evidence that the lower doses are effective, many sources still recommend the higher doses, and there don't seem to be any known adverse effects. If I'm going to the trouble of buying and pinning, I want to be sure, or at least as sure as I can be, that I'm getting the full benefits.
Click to expand...
I think the issue I have with the "many sources" is for the most part these are just resellers repeating the same message. A copy pasta error. Not real data, it got posted once and then quickly propagates through. Similar to the BPC-157 cancer stuff. I found one old article that was basically a Dr. musing about a theoretical cancer risk based on the "assumed" mechanism. This has translated into BPC can cause cancer.

Just for clarity I'm not saying that I have the correct answers, just that there is a lot of information that gets propagated through the community that is either wrong or has zero actual science behind it. But after multiple layers it gets hard to find the orgins.
 
cheaperseeker said:
I replied to your post, but also referenced info about Epitalon and cancer from Researcher6076's post. Sorry for the confusion.
Click to expand...
Got it. Found it. Sorry it took a while for me to find the reference. You're absolutely right about the increase in Mouse cancer with vilon in this study. For what it's worth , in the conclusions to the article the researchers concluded that epitalon was protective against cancer. They concluded vilon was not protective against cancer. And they also concluded that the increase in cancer they observed in this genetically modified Mouse population was not representative of violin being a cancer threat. They concluded the increase in cancer was model specific, referring just to these genetically modified mice. But you're very right to bring up the concern.

To the point of my possible research protocols, epitalon + thymalin seem the two peptides of choice for people with aging immune systems that are otherwise generally normal. But epitalon + vilon are the peptides of choice for people with overactive immune systems and autoimmune issues. Modulating the immune system for that population is the intention. The theoretical risk is modulating the immune system of someone with a weak immune system might reduce its ability to detect and destroy precancerous cells.

I look forward to continuing this discussion with all of you. I really enjoy hanging out with some smart people. Now I have all I have to do is find the vilon, it's a bit less available than some of the other peptides.
 
cheaperseeker said:
That's pretty much why I've stuck to the higher dosage. I haven't seen any reliable, research-based evidence that the lower doses are effective, many sources still recommend the higher doses, and there don't seem to be any known adverse effects. If I'm going to the trouble of buying and pinning, I want to be sure, or at least as sure as I can be, that I'm getting the fu
Researcher6076 said:
Got it. Found it. Sorry it took a while for me to find the reference. You're absolutely right about the increase in Mouse cancer with vilon in this study. For what it's worth , in the conclusions to the article the researchers concluded that epitalon was protective against cancer. They concluded vilon was not protective against cancer. And they also concluded that the increase in cancer they observed in this genetically modified Mouse population was not representative of violin being a cancer threat. They concluded the increase in cancer was model specific, referring just to these genetically modified mice. But you're very right to bring up the concern.

To the point of my possible research protocols, epitalon + thymalin seem the two peptides of choice for people with aging immune systems that are otherwise generally normal. But epitalon + vilon are the peptides of choice for people with overactive immune systems and autoimmune issues. Modulating the immune system for that population is the intention. The theoretical risk is modulating the immune system of someone with a weak immune system might reduce its ability to detect and destroy precancerous cells.

I look forward to continuing this discussion with all of you. I really enjoy hanging out with some smart people. Now I have all I have to do is find the vilon, it's a bit less available than some of the other peptides.
Click to expand...
I never really looked into it deeply, I just skimmed thru it while researching epitalon
Click to expand...
I never really looked into it deeply, I just skimmed thru it while researching epitalon
 
cheaperseeker said:
I replied to your post, but also referenced info about Epitalon and cancer from Researcher6076's post. Sorry for the confusion. I’m out in the field with my business, but I will look that up when I get to my office. I know Weinstein was talking about the
Click to expand...

CNCCurrency said:
I never really looked into it deeply, I just skimmed thru it while researching epitalon
Click to expand...
 

Attachments

  • image(8).webp
    image(8).webp
    48.1 KB · Views: 5
  • image(9).webp
    image(9).webp
    34.1 KB · Views: 5
Researcher6076 said:
It's hard to find a strait, researched answer with dosing for Epitalon. Yes, the early Russian clinical trials started with epitalamin at 10mg/day. But the later Russian trials switched to Epitalon and kept the dose to 10mg day. And because epitalamin is a natural extract there is no reliable dose comparison to Epitalon. Some say 1000:1, but some say 3:1. I have found there is not reliable ratio. Yes, in our community there are lot of dosing claims, but I haven't found any actually tied to repeatable research. And 10mg of Epitalon gets used a lot with no adverse reactions reportee, right? I'm not saying you should use 10mg. Just saying there is legitimate confusion, and no clear answer.
Click to expand...
I agree with you that there’s legitimate confusion around Epitalon dosing. The Russian literature isn’t the clearest, especially with the shift from epithalamin, apineal extract, to the isolated tetrapeptide Epitalon while keeping similar milligram dosing.

My reason for mentioning it is that some people jump straight to 10 mg assuming it’s the clearly established dose, when in reality the literature leaves quite a bit of room for interpretation.

Speaking from experience, starting that high didn’t feel great for me. Once I lowered the dose, the experience was completely different.
 
Speaking from experience, starting that high didn’t feel great for me. Once I lowered the dose, the experience was completely different.
Click to expand...

How was it different, and how would you go about dosing now, given what you learned?
 
Jfrick11 said:
I agree with you that there’s legitimate confusion around Epitalon dosing. The Russian literature isn’t the clearest, especially with the shift from epithalamin, apineal extract, to the isolated tetrapeptide Epitalon while keeping similar milligram dosing.

My reason for mentioning it is that some people jump straight to 10 mg assuming it’s the clearly established dose, when in reality the literature leaves quite a bit of room for interpretation.

Speaking from experience, starting that high didn’t feel great for me. Once I lowered the dose, the experience was completely different.
Click to expand...
100% I wouldn't recommend anyone start at 10mg. I ran 1.6mg for 6 days, so a total of 10mg. That worked great for me, no side effects. I wanted for 3 months before running the full 100mg protocol.

The good news is there is great safety hisyory on these peptides. We really need some new clinical trials, but there isn't interest it seems. For sure, no big money to be made with these old widely available peptides.
 
Researcher6076 said:
100% I wouldn't recommend anyone start at 10mg. I ran 1.6mg for 6 days, so a total of 10mg. That worked great for me, no side effects. I wanted for 3 months before running the full 100mg protocol.

The good news is there is great safety hisyory on these peptides. We really need some new clinical trials, but there isn't interest it seems. For sure, no big money to be made with these old widely available peptides.
Click to expand...
  • Research is out there if you look
  1. Aina, F. O., Fadare, J. O., Deji-Dada, O. O., & Agbesanwa, T. A. (2021). Increasing Burden of Aging Population on Health Services Utilization: A Myth or Reality in a Country with Predominantly Young Population. Aging Medicine and Healthcare, 12(2), 41–45. 10.33879/AMH.122.2020.07023
  2. Al-dulaimi, S., Matta, S., Slijepcevic, P., & Roberts, T. (2024). 5-aza-2′-deoxycytidine induces telomere dysfunction in breast cancer cells. Biomedicine & Pharmacotherapy, 178, 117173. 10.1016/j.biopha.2024.117173
  3. Anisimov, V. N., & Khavinson, V. K. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology (Dordrecht), 11(2), 139–149. 10.1007/s10522-009-9249-8
  4. Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 26(6), 2691. 10.3390/ijms26062691
  5. Beard, J. R., Officer, A., Carvalho, I. A., Sadana, R., Pot, A. M., Michel, J. P., Lloyd-Sherlock, P., Epping-Jordan, J. E., Peeters, G. M., Mahanani, W. R., Thiyagarajan, J. A., & Chatterij, S. (2016). The World report on ageing and health: a policy framework for healthy ageing.10.1016/S0140-6736(15)00516-4
  6. Bernardes de Jesus, B., & Blasco, M. A. (2013). Telomerase at the intersection of cancer and aging. Trends in Genetics, 29(9), 513–520. 10.1016/j.tig.2013.06.007
  7. Bernardes de Jesus, B., Vera, E., Schneeberger, K., Tejera, A. M., Ayuso, E., Bosch, F., & Blasco, M. A. (2012). Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Molecular Medicine, 4(8), 691–704. 10.1002/emmm.201200245
  8. Bischoff-Ferrari, H. A., Gängler, S., Wieczorek, M., Belsky, D. W., Ryan, J., Kressig, R. W., Stähelin, H. B., Theiler, R., Dawson-Hughes, B., Rizzoli, R., Vellas, B., Rouch, L., Guyonnet, S., Egli, A., Orav, E. J., Willett, W., & Horvath, S. (2025). Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging, 5(3), 376–385. 10.1038/s43587-024-00793-y
  9. Boccardi, V. (2025). From telomeres and senescence to integrated longevity medicine: redefining the path to extended healthspan. Biogerontology (Dordrecht), 26(3), 107. 10.1007/s10522-025-10246-7
  10. Chung, I., Osterwald, S., Deeg, K. I., & Rippe, K. (2012). PML body meets telomere. Nucleus (Austin, Tex.), 3(3), 263–275. 10.4161/nucl.20326
  11. de Jesus, B. B., Schneeberger, K., Vera, E., Tejera, A., Harley, C. B., & Blasco, M. A. (2011). The telomerase activator TA‐65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell, 10(4), 604–621. 10.1111/j.1474-9726.2011.00700.x
  12. De Vitis, M., Berardinelli, F., & Sgura, A. (2018). Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT). International Journal of Molecular Sciences, 19(2), 606. 10.3390/ijms19020606
  13. Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021). Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nature Reviews. Molecular Cell Biology, 22(2), 75–95. 10.1038/s41580-020-00314-w
  14. Dimri, G., Band, H., & Band, V. (2005). Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Research, 7(4), 171–179. 10.1186/bcr1275
  15. Dixit, V., Chaubey, K. K., Dayal, D., Chole, P. B., B. T., M., Bachheti, R. K., Gupta, P. C., Bachheti, A., & Worku, L. A. (2025). Natural Products in Aging: Cellular Mechanisms and Emerging Therapeutics for Age‐Related Disorders. Journal of Aging Research, 2025(1)10.1155/jare/6868732
  16. Du, N., Yang, R., Jiang, S., Niu, Z., Zhou, W., Liu, C., Gao, L., & Sun, Q. (2024). Anti-Aging Drugs and the Related Signal Pathways. Biomedicines, 12(1), 127. 10.3390/biomedicines12010127
  17. Ducrest, A., Amacker, M., Mathieu, Y. D., Cuthbert, A. P., Trott, D. A., Newbold, R. F., Nabholz, M., & Lingner, J. (2001). Regulation of Human Telomerase Activity: Repression by Normal Chromosome 3 Abolishes Nuclear Telomerase Reverse Transcriptase Transcripts but Does Not Affect c-Myc Activity. Cancer Research, 61(20), 7594–7602. http://cancerres.aacrjournals.org/cgi/content/abstract/61/20/7594
  18. El Hajj, J., Nguyen, E., Liu, Q., Bouyer, C., Adriaenssens, E., Hilal, G., & Ségal-Bendirdjian, E. (2018). Telomerase regulation by the long non-coding RNA H19 in human acute promyelocytic leukemia cells. Molecular Cancer, 17(1), 85–85. 10.1186/s12943-018-0835-8
  19. Fedoreyeva, L. I., Kireev, I. I., Khavinson, V. K., & Vanyushin, B. F. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 76(11), 1210–1219. 10.1134/S0006297911110022
  20. Feng, J., Funk, W. D., Wang, S. S., Weinrich, S. L., Avilion, A. A., Chiu, C. P., Adams, R. R., Chang, E., Allsopp, R. C., & Yu, J. (1995). The RNA component of human telomerase. Science, 269(5228), 1236–1241. 10.1126/science.7544491
  21. Fouad, Y. A., & Aanei, C. (2017). Revisiting the hallmarks of cancer. American Journal of Cancer Research, 7(5), 1016–1036. https://www.ncbi.nlm.nih.gov/pubmed/28560055
  22. Franceschi, C., Garagnani, P., Morsiani, C., Conte, M., Santoro, A., Grignolio, A., Monti, D., Capri, M., & Salvioli, S. (2018). The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates. Frontiers in Medicine, 5, 61–61. 10.3389/fmed.2018.00061
  23. Greider, C. W., & Blackburn, E. H. (1985). Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell, 43(2), 405–413. 10.1016/0092-8674(85)90170-9
  24. Guarente, L., Sinclair, D. A., & Kroemer, G. (2024). Human trials exploring anti-aging medicines. Cell Metabolism, 36(2), 354–376. 10.1016/j.cmet.2023.12.007
  25. Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022). Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy, 7(1), 391–40. 10.1038/s41392-022-01251-0
  26. Guo, Y., Zhang, Y., Wang, Q., Yu, J., Wan, Q., Huang, J., & Fang, S. (2023). Alternative telomere maintenance mechanism in Alligator sinensis provides insights into aging evolution. iScience, 26(1), 105850. 10.1016/j.isci.2022.105850
  27. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46. 10.1158/2159-8290.cd-21-1059
  28. Hanahan, D., & Weinberg, R. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144(5), 646–674. 10.1016/j.cell.2011.02.013
  29. Henson, J. D., Lau, L. M., Koch, S., Martin La Rotta, N., Dagg, R. A., & Reddel, R. R. (2017). The C-Circle Assay for alternative-lengthening-of-telomeres activity. Methods (San Diego, Calif.), 114, 74–84. 10.1016/j.ymeth.2016.08.016
 
CNCCurrency said:
  • Research is out there if you look
Hu, Y., Shi, G., Zhang, L., Li, F., Jiang, Y., Jiang, S., Ma, W., Zhao, Y., Songyang, Z., & Huang, J. (2016). Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX. Scientific Reports, 6(1), 32280–32280. 10.1038/srep32280
Huang, X., Huang, L., Lu, J., Cheng, L., Wu, D., Li, L., Zhang, S., Lai, X., & Xu, L. (2025). The relationship between telomere length and aging-related diseases. Clinical and Experimental Medicine, 25(1), 72. 10.1007/s10238-025-01608-z
Jaul, E., & Barron, J. (2017). Age-Related Diseases and Clinical and Public Health Implications for the 85 Years Old and Over Population. Frontiers in Public Health, 5, 335–335. 10.3389/fpubh.2017.00335
Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bulletin of Experimental Biology and Medicine, 135(6), 590–592. 10.1023/A:1025493705728
Khavinson, V. K., Izmaylov, D. M., Obukhova, L. K., & Malinin, V. V. (2000). Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development, 120(1), 141–149. 10.1016/S0047-6374(00)00217-7
Khavinson, V. K., Kormilets, D. Y., & Mar’yanovich, A. T. (2017). Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan. Bulletin of Experimental Biology and Medicine, 163(5), 671–676. 10.1007/s10517-017-3876-x
Khavinson, V. K., Solovyov, A. Y., & Shataeva, L. K. (2008). Melting of DNA Double Strand after Binding to Geroprotective Tetrapeptide. Bulletin of Experimental Biology and Medicine, 146(5), 624–626. 10.1007/s10517-009-0342-4
Khavinson, V. K., Zemchikhina, V. N., Trofimova, S. V., & Malinin, V. V. (2003). Effects of Peptides on Proliferative Activity of Retinal and Pigmented Epithelial Cells. Bulletin of Experimental Biology and Medicine, 135(6), 597–599. 10.1023/A:1025497806636
Khavinson, V., Diomede, F., Mironova, E., Linkova, N., Trofimova, S., Trubiani, O., Caputi, S., & Sinjari, B. (2020). AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules (Basel, Switzerland), 25(3), 609. 10.3390/molecules25030609
Kiecolt-Glaser, J. K., Epel, E. S., Belury, M. A., Andridge, R., Lin, J., Glaser, R., Malarkey, W. B., Hwang, B. S., & Blackburn, E. (2013). Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial. Brain, Behavior, and Immunity, 28, 16–24. 10.1016/j.bbi.2012.09.004
Leão, R., Apolónio, J. D., Lee, D., Figueiredo, A., Tabori, U., & Castelo-Branco, P. (2018). Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. Journal of Biomedical Science, 25(1), 22–22. 10.1186/s12929-018-0422-8
Lewis, K. A., & Tollefsbol, T. O. (2016). Regulation of the Telomerase Reverse Transcriptase Subunit through Epigenetic Mechanisms. Frontiers in Genetics, 7, 83–83. 10.3389/fgene.2016.00083
Lin, C. G., Näger, A. C., Lunardi, T., Vančevska, A., Lossaint, G., & Lingner, J. (2021). The human telomeric proteome during telomere replication. Nucleic Acids Research, 49(21), 12119–12135. 10.1093/nar/gkab1015
Lin’kova, N. S., Drobintseva, A. O., Orlova, O. A., Kuznetsova, E. P., Polyakova, V. O., Kvetnoy, I. M., & Khavinson, V. K. (2016). Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bulletin of Experimental Biology and Medicine, 161(1), 175–178. 10.1007/s10517-016-3370-x
Medrzycki, M., Zhang, Y., Zhang, W., Cao, K., Pan, C., Lailler, N., McDonald, J. F., Bouhassira, E. E., & Fan, Y. (2014). Histone H1.3 Suppresses H19 Noncoding RNA Expression and Cell Growth of Ovarian Cancer Cells. Cancer Research (Chicago, Ill.), 74(22), 6463–6473. 10.1158/0008-5472.CAN-13-2922
Menassa, M., Stronks, K., Khatmi, F., Roa Díaz, Z. M., Espinola, O. P., Gamba, M., Itodo, O. A., Buttia, C., Wehrli, F., Minder, B., Velarde, M. R., & Franco, O. H. (2023). Concepts and definitions of healthy ageing: a systematic review and synthesis of theoretical models. EClinicalMedicine, 56, 101821. 10.1016/j.eclinm.2022.101821
Murga, M., Jaco, I., Fan, Y., Soria, R., Martinez-Pastor, B., Cuadrado, M., Yang, S., Blasco, M. A., Skoultchi, A. I., & Fernandez-Capetillo, O. (2007). Global chromatin compaction limits the strength of the DNA damage response. The Journal of Cell Biology, 178(7), 1101–1108. 10.1083/jcb.200704140
O'Callaghan, N. J., & Fenech, M. (2011). A quantitative PCR method for measuring absolute telomere length. Biological Procedures Online, 13(1), 3. 10.1186/1480-9222-13-3
O'Sullivan, R. J., & Almouzni, G. (2014). Assembly of telomeric chromatin to create ALTernative endings. Trends in Cell Biology, 24(11), 675–685. 10.1016/j.tcb.2014.07.007
O'Sullivan, R. J., Arnoult, N., Lackner, D. H., Oganesian, L., Haggblom, C., Corpet, A., Almouzni, G., & Karlseder, J. (2014). Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1. Nature Structural & Molecular Biology, 21(2), 167–174. 10.1038/nsmb.2754
Perrem, K., Colgin, L. M., Neumann, A. A., Yeager, T. R., & Reddel, R. R. (2001). Coexistence of Alternative Lengthening of Telomeres and Telomerase in hTERT-Transfected GM847 Cells. Molecular and Cellular Biology, 21(12), 3862–3875. 10.1128/MCB.21.12.3862-3875.2001
Plyasova, A. A., & Zhdanov, D. D. (2021). Alternative Splicing of Human Telomerase Reverse Transcriptase (hTERT) and Its Implications in Physiological and Pathological Processes. Biomedicines, 9(5), 526. 10.3390/biomedicines9050526
Rose, A. M., Goncalves, T., Cunniffe, S., Geiller, H. E. B., Kent, T., Shepherd, S., Ratnaweera, M., O’Sullivan, R., Gibbons, R., & Clynes, D. (2023). Induction of the alternative lengthening of telomeres pathway by trapping of proteins on DNA. Nucleic Acids Research, 51(13), 6509–6527. 10.1093/nar/gkad150
Scaffidi, P. (2016). Histone H1 alterations in cancer. Biochimica Et Biophysica Acta, 1859(3), 533–539. 10.1016/j.bbagrm.2015.09.008
Schellnegger, M., Hofmann, E., Carnieletto, M., & Kamolz, L. (2024). Unlocking longevity: the role of telomeres and its targeting interventions. Frontiers in Aging, 5, 1339317. 10.3389/fragi.2024.1339317
Tenchov, R., Sasso, J. M., Wang, X., & Zhou, Q. A. (2024). Aging Hallmarks and Progression and Age-Related Diseases: A Landscape View of Research Advancement. ACS Chemical Neuroscience, 15(1), 1–30. 10.1021/acschemneuro.3c00531
Torres, C. M., Biran, A., Burney, M. J., Patel, H., Henser-Brownhill, T., Cohen, A. S., Li, Y., Ben-Hamo, R., Nye, E., Spencer-Dene, B., Chakravarty, P., Efroni, S., Matthews, N., Misteli, T., Meshorer, E., & Scaffidi, P. (2016). The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity. Science, 353(6307), 1514. 10.1126/science.aaf1644
Vaiserman, A., & Krasnienkov, D. (2021). Telomere Length as a Marker of Biological Age: State-of-the-Art, Open Issues, and Future Perspectives. Frontiers in Genetics, 11, 630186. 10.3389/fgene.2020.630186
Whittemore, K., Vera, E., Martínez-Nevado, E., Sanpera, C., & Blasco, M. A. (2019). Telomere shortening rate predicts species life span. Proceedings of the National Academy of Sciences, 116(30), 15122–15127. 10.1073/pnas.1902452116
Yik, M. Y., Azlan, A., Rajasegaran, Y., Rosli, A., Yusoff, N. M., & Moses, E. J. (2021). Mechanism of Human Telomerase Reverse Transcriptase (hTERT) Regulation and Clinical Impacts in Leukemia. Genes, 12(8), 1188. 10.3390/genes12081188
Yu, Q., Gates, P., Rogers, S., Mikicic, I., Elewa, A., Salomon, F., Lachnit, M., Caldarelli, A., Flores-Rodriguez, N., Cesare, A. J., Simon, A., & Maximina Yun. (2022). Telomerase-independent maintenance of telomere length in a vertebrate. bioRxiv, 10.1101/2022.03.25.485759
Yu-Zun Guo, Yi Zhang, Qing Wang, Jun Yu, Qiu-Hong Wan, Jun Huang, & Sheng-Guo Fang. (2023). Alternative telomere maintenance mechanism in Alligator sinensis provides insights into aging evolution Alternative telomere maintenance mechanism in Alligator sinensis provides insights into aging evolution. iScience, 26(1), 105850. https://doaj.org/article/2a12a0996a8c44629631ff1c750e5ce5
Zhou, D., Luo, M., Huang, S., Saimaiti, A., Shang, A., Gan, R., & Li, H. (2021). Effects and Mechanisms of Resveratrol on Aging and Age-Related Diseases. Oxidative Medicine and Cellular Longevity, 2021(1), 9932218. 10.1155/2021/9932218
Click to expand...
 
CNCCurrency said:
  • Research is out there if you look
  1. Aina, F. O., Fadare, J. O., Deji-Dada, O. O., & Agbesanwa, T. A. (2021). Increasing Burden of Aging Population on Health Services Utilization: A Myth or Reality in a Country with Predominantly Young Population. Aging Medicine and Healthcare, 12(2), 41–45. 10.33879/AMH.122.2020.07023
  2. Al-dulaimi, S., Matta, S., Slijepcevic, P., & Roberts, T. (2024). 5-aza-2′-deoxycytidine induces telomere dysfunction in breast cancer cells. Biomedicine & Pharmacotherapy, 178, 117173. 10.1016/j.biopha.2024.117173
  3. Anisimov, V. N., & Khavinson, V. K. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology (Dordrecht), 11(2), 139–149. 10.1007/s10522-009-9249-8
  4. Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 26(6), 2691. 10.3390/ijms26062691
  5. Beard, J. R., Officer, A., Carvalho, I. A., Sadana, R., Pot, A. M., Michel, J. P., Lloyd-Sherlock, P., Epping-Jordan, J. E., Peeters, G. M., Mahanani, W. R., Thiyagarajan, J. A., & Chatterij, S. (2016). The World report on ageing and health: a policy framework for healthy ageing.10.1016/S0140-6736(15)00516-4
  6. Bernardes de Jesus, B., & Blasco, M. A. (2013). Telomerase at the intersection of cancer and aging. Trends in Genetics, 29(9), 513–520. 10.1016/j.tig.2013.06.007
  7. Bernardes de Jesus, B., Vera, E., Schneeberger, K., Tejera, A. M., Ayuso, E., Bosch, F., & Blasco, M. A. (2012). Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Molecular Medicine, 4(8), 691–704. 10.1002/emmm.201200245
  8. Bischoff-Ferrari, H. A., Gängler, S., Wieczorek, M., Belsky, D. W., Ryan, J., Kressig, R. W., Stähelin, H. B., Theiler, R., Dawson-Hughes, B., Rizzoli, R., Vellas, B., Rouch, L., Guyonnet, S., Egli, A., Orav, E. J., Willett, W., & Horvath, S. (2025). Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging, 5(3), 376–385. 10.1038/s43587-024-00793-y
  9. Boccardi, V. (2025). From telomeres and senescence to integrated longevity medicine: redefining the path to extended healthspan. Biogerontology (Dordrecht), 26(3), 107. 10.1007/s10522-025-10246-7
  10. Chung, I., Osterwald, S., Deeg, K. I., & Rippe, K. (2012). PML body meets telomere. Nucleus (Austin, Tex.), 3(3), 263–275. 10.4161/nucl.20326
  11. de Jesus, B. B., Schneeberger, K., Vera, E., Tejera, A., Harley, C. B., & Blasco, M. A. (2011). The telomerase activator TA‐65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. Aging Cell, 10(4), 604–621. 10.1111/j.1474-9726.2011.00700.x
  12. De Vitis, M., Berardinelli, F., & Sgura, A. (2018). Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT). International Journal of Molecular Sciences, 19(2), 606. 10.3390/ijms19020606
  13. Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021). Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nature Reviews. Molecular Cell Biology, 22(2), 75–95. 10.1038/s41580-020-00314-w
  14. Dimri, G., Band, H., & Band, V. (2005). Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Research, 7(4), 171–179. 10.1186/bcr1275
  15. Dixit, V., Chaubey, K. K., Dayal, D., Chole, P. B., B. T., M., Bachheti, R. K., Gupta, P. C., Bachheti, A., & Worku, L. A. (2025). Natural Products in Aging: Cellular Mechanisms and Emerging Therapeutics for Age‐Related Disorders. Journal of Aging Research, 2025(1)10.1155/jare/6868732
  16. Du, N., Yang, R., Jiang, S., Niu, Z., Zhou, W., Liu, C., Gao, L., & Sun, Q. (2024). Anti-Aging Drugs and the Related Signal Pathways. Biomedicines, 12(1), 127. 10.3390/biomedicines12010127
  17. Ducrest, A., Amacker, M., Mathieu, Y. D., Cuthbert, A. P., Trott, D. A., Newbold, R. F., Nabholz, M., & Lingner, J. (2001). Regulation of Human Telomerase Activity: Repression by Normal Chromosome 3 Abolishes Nuclear Telomerase Reverse Transcriptase Transcripts but Does Not Affect c-Myc Activity. Cancer Research, 61(20), 7594–7602. http://cancerres.aacrjournals.org/cgi/content/abstract/61/20/7594
  18. El Hajj, J., Nguyen, E., Liu, Q., Bouyer, C., Adriaenssens, E., Hilal, G., & Ségal-Bendirdjian, E. (2018). Telomerase regulation by the long non-coding RNA H19 in human acute promyelocytic leukemia cells. Molecular Cancer, 17(1), 85–85. 10.1186/s12943-018-0835-8
  19. Fedoreyeva, L. I., Kireev, I. I., Khavinson, V. K., & Vanyushin, B. F. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 76(11), 1210–1219. 10.1134/S0006297911110022
  20. Feng, J., Funk, W. D., Wang, S. S., Weinrich, S. L., Avilion, A. A., Chiu, C. P., Adams, R. R., Chang, E., Allsopp, R. C., & Yu, J. (1995). The RNA component of human telomerase. Science, 269(5228), 1236–1241. 10.1126/science.7544491
  21. Fouad, Y. A., & Aanei, C. (2017). Revisiting the hallmarks of cancer. American Journal of Cancer Research, 7(5), 1016–1036. https://www.ncbi.nlm.nih.gov/pubmed/28560055
  22. Franceschi, C., Garagnani, P., Morsiani, C., Conte, M., Santoro, A., Grignolio, A., Monti, D., Capri, M., & Salvioli, S. (2018). The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates. Frontiers in Medicine, 5, 61–61. 10.3389/fmed.2018.00061
  23. Greider, C. W., & Blackburn, E. H. (1985). Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell, 43(2), 405–413. 10.1016/0092-8674(85)90170-9
  24. Guarente, L., Sinclair, D. A., & Kroemer, G. (2024). Human trials exploring anti-aging medicines. Cell Metabolism, 36(2), 354–376. 10.1016/j.cmet.2023.12.007
  25. Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022). Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy, 7(1), 391–40. 10.1038/s41392-022-01251-0
  26. Guo, Y., Zhang, Y., Wang, Q., Yu, J., Wan, Q., Huang, J., & Fang, S. (2023). Alternative telomere maintenance mechanism in Alligator sinensis provides insights into aging evolution. iScience, 26(1), 105850. 10.1016/j.isci.2022.105850
  27. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46. 10.1158/2159-8290.cd-21-1059
  28. Hanahan, D., & Weinberg, R. (2011). Hallmarks of Cancer: The Next Generation. Cell, 144(5), 646–674. 10.1016/j.cell.2011.02.013
  29. Henson, J. D., Lau, L. M., Koch, S., Martin La Rotta, N., Dagg, R. A., & Reddel, R. R. (2017). The C-Circle Assay for alternative-lengthening-of-telomeres activity. Methods (San Diego, Calif.), 114, 74–84. 10.1016/j.ymeth.2016.08.016
Click to expand...
Yes, lots of research on aging. But only, Anisimov & Khavinson (2010) above included any reference to Epitalon, Right? And it was a review, not new research. And only Bischoff‑Ferrari et al., 2025 was an actual human trial and it was vitamins and exercise. For us "researchers" trying to decide if we want to give our subjects 10mg of Epitalon or a smaller dose, we have limited data to guide that decision.
 
Researcher6076 said:
Yes, lots of research on aging. But only, Anisimov & Khavinson (2010) above included any reference to Epitalon, Right? And it was a review, not new research. And only Bischoff‑Ferrari et al., 2025 was an actual human trial and it was vitamins and exercise. For us "researchers" trying to decide if we want to give our subjects 10mg of Epitalon or a smaller dose, we have limited data to guide that decision.
Click to expand...
Claro Que Black Woman GIF by iOne Digital
 
You must log in or register to reply here.

Trending Topics

Latest Posts

Forum Statistics

Threads
18,337
Posts
191,193
Members
61,441
Newest
bibiche
Back
Top Bottom